Presenting to the nephrology clinic with a 3-day history of hand tremors, headaches, and r… — USMLE Step 3

Presenting to the nephrology clinic with a 3-day history of hand tremors, headaches, and reduced urine output, a 52-year-old male recipient of a deceased-donor renal allograft undergoes urgent evaluation. He is currently 6 months post-transplantation.

His maintenance immunosuppressive regimen includes tacrolimus, mycophenolate mofetil, and prednisone. Two weeks ago, he was diagnosed with oropharyngeal candidiasis by his primary care physician and completed a 14-day course of oral fluconazole.

Vital signs are:

Parameter	Value
Temperature	37.1°C (98.8°F)
Blood pressure	158/96 mmHg
Pulse	84/min

Physical examination reveals a fine resting tremor in the bilateral upper extremities. The transplanted kidney is non-tender to palpation.

Laboratory results:

Test	Result	Reference Range
Potassium	5.4 mEq/L	3.5-5.0 mEq/L
Blood urea nitrogen	48 mg/dL	8-20 mg/dL
Serum creatinine	3.1 mg/dL	0.7-1.3 mg/dL

*Baseline serum creatinine was 1.3 mg/dL one month ago.*

Which of the following is the most appropriate next step in the management and monitoring of this patient?

A
Administer intravenous methylprednisolone and increase the maintenance dose of oral prednisone
B
Schedule an ultrasound-guided renal allograft biopsy to evaluate for acute rejection
Order a serum tacrolimus trough level and withhold the next scheduled dose of tacrolimusAnswer
D
Order a non-contrast CT scan of the abdomen and pelvis to evaluate for post-renal obstruction
E
Administer intravenous calcium gluconate, regular insulin, and dextrose immediately

Answer

The most appropriate next step is to order a serum tacrolimus trough level and withhold the next scheduled dose of tacrolimus.

This patient is presenting with acute calcineurin inhibitor (CNI) toxicity. Tacrolimus is metabolized primarily by the hepatic cytochrome P450 3A4 (CYP3A4) system. Fluconazole is a potent inhibitor of CYP3A4. The concurrent use of fluconazole drastically reduces tacrolimus clearance, leading to supratherapeutic levels. CNI toxicity manifests with dose-dependent acute kidney injury (due to afferent arteriolar vasoconstriction), new-onset or worsening hypertension, neurotoxicity (e.g., resting tremors, headaches, seizures), and metabolic derangements such as hyperkalemia. Because the clinical picture strongly points to drug toxicity rather than acute cellular rejection (which would typically present with graft tenderness and fever), the most appropriate next step in monitoring and evaluation is to withhold the next dose of tacrolimus and measure a serum trough level to confirm the diagnosis.

Step-by-Step Solution

Analyze the patient's timeline and new medications.

The patient was recently started on fluconazole, a potent inhibitor of the cytochrome P450 (CYP3A4) enzyme system.

Identifying new medications is critical to uncovering drug-drug interactions in transplant patients.

Correlate the new medication with the maintenance regimen.

Tacrolimus is extensively metabolized by CYP3A4. Fluconazole inhibition leads to decreased tacrolimus clearance and supratherapeutic systemic levels.

Understanding the pharmacokinetic pathways reveals the mechanism of potential toxicity.

Evaluate the clinical presentation and laboratory results against known toxicities.

The patient exhibits classic signs of calcineurin inhibitor (CNI) toxicity: acute kidney injury (creatinine 3.1 mg/dL), neurotoxicity (tremors, headache), hypertension, and hyperkalemia.

Differentiating CNI toxicity from acute cellular rejection (which typically features graft tenderness and fever) dictates the management pathway.

Determine the optimal sequencing for treatment and monitoring.

The immediate priority is to halt the offending agent (withhold tacrolimus) and confirm the diagnosis non-invasively (check trough level) before pursuing invasive biopsies.

Standard of care requires establishing therapeutic drug levels before escalating to immunosuppressive therapies or invasive diagnostics.

Key Concept

Calcineurin inhibitor toxicity secondary to CYP3A4 inhibition requires immediate dose withholding and serum level monitoring before invasive diagnostics.

Estimated Time:2m 0s

Question

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Topics

More questions from this topic